Advertisement

Lewy Body Dementia

Published:August 22, 2018DOI:https://doi.org/10.1016/j.cger.2018.06.007

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lewy F.
        Paralysis agitans. I. Pathologische anatomie.
        in: Handbuch der Neurologie. vol. 3. Springer Verlag, Berlin1912: 920-933
        • Spillantini M.
        • Schmidt M.
        • Lee V.
        • et al.
        α-Synuclein in Lewy bodies.
        Nature. 1997; 388: 839-840
        • Varkey J.
        • Isas J.
        • Mizuno N.
        • et al.
        Membrane curvature induction and tubulation are common features of α-synuclein inclusion formation during aging.
        J Biol Chem. 2010; 285: 32486-32493
        • McCann H.
        • Stevens C.
        • Cartwright H.
        • et al.
        α-Synucleinopathy phenotypes.
        Parkinsonism Relat Disord. 2014; 20: S62-S67
        • Savica R.
        • Grossardt B.
        • Bower J.
        • et al.
        Diagnosed synucleinopathies with parkinsonism: a population-based study.
        JAMA Neurol. 2017; 74: 839-846
        • Emre M.
        • Aarsland D.
        • Brown R.
        Clinical diagnostic criteria for dementia associated with Parkinson’s disease.
        Mov Disord. 2007; 22: 1689-1707
        • Palmqvist S.
        • Hansson O.
        • Minthon L.
        • et al.
        Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer’s disease with common cognitive tests.
        Int J Geriatr Psychiatry. 2009; 24: 1405-1412
        • Vann Jones S.
        • O’Brien J.
        The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies.
        Psychol Med. 2014; 44: 673-683
        • Galasko D.
        Lewy body disorders.
        Neurol Clin. 2017; 35: 325-338
        • Lippa C.
        • Fujiwara H.
        • Mann D.
        • et al.
        Lewy bodies contain altered alpha-synuclein in brains of many familiar Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes.
        Am J Pathol. 1998; 153: 1365-1370
        • Uchikado H.
        • Lin W.
        • DeLucia M.
        • et al.
        Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy.
        J Neuropathol Exp Neurol. 2006; 65: 685-697
        • Rabinovici G.
        • Carrillo M.
        • Forman M.
        • et al.
        Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development.
        Alzheimers Dement. 2016; 3: 83-91
        • Bras J.
        • Guerreiro R.
        • Darwent L.
        • et al.
        Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.
        Hum Mol Genet. 2014; 23: 6139-6146
        • Tsuang D.
        • Leverenz J.
        • Lopez O.
        • et al.
        APOE ε4 increases risk for dementia in pure synucleinopathies.
        JAMA Neurol. 2013; 70: 727-735
        • Stefanis L.
        α-Synuclein in Parkinson’s disease.
        Cold Spring Harb Perspect Med. 2012; 2: a009399
        • Goedert M.
        • Jakes R.
        • Spillantini M.
        The synucleinopathies: twenty years on.
        J Parkinsons Dis. 2017; 7: S53-S71
        • Braak H.
        • Del Tredici K.
        • Rub U.
        • et al.
        Staging of brain pathology related to sporadic Parkinson’s disease.
        Neurobiol Aging. 2003; 24: 197-211
        • Dickson D.
        • Fujishiro H.
        • DelleDonne A.
        • et al.
        Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease.
        Acta Neuropathol. 2008; 115: 436-444
        • Schneider J.
        • Arvanitakis Z.
        • Yu L.
        • et al.
        Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.
        Brain. 2012; 135: 3005-3014
        • Nelson P.T.
        • Jicha G.A.
        • Kryscio R.J.
        • et al.
        Low sensitivity in clinical diagnosis of dementia with Lewy bodies.
        J Neurol. 2010; 257: 359-366
        • McKeith I.
        • Dickson D.
        • Lowe J.
        • et al.
        Diagnosis and management of dementia with Lewy bodies.
        Neurology. 2005; 65: 1863-1872
        • Postuma R.
        • Berg D.
        • Stern M.
        • et al.
        Abolishing the 1-year rule: how much evidence will be enough?.
        Mov Disord. 2016; 31: 1623-1627
        • Whitwell J.
        • Weigand S.
        • Shiung M.
        • et al.
        Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease.
        Brain. 2007; I30: 708-719
        • Tiraboschi P.
        • Salmon D.
        • Hansen L.
        • et al.
        What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia?.
        Brain. 2006; 129: 729-735
        • Petrova M.
        • Mehrabian-Spasova A.
        • Aarsland D.
        • et al.
        Clinical and neuropsychological differences between mild Parkinson’s disease dementia and dementia with Lewy bodies.
        Dement Geriatr Cogn Dis Extra. 2015; 5: 212-220
        • Bodis-Wollner I.
        Retinopathy in Parkinson disease.
        J Neural Transm (Vienna). 2009; 116: 1493-1501
        • Boeve B.
        REM sleep behavior disorder: updated review of the core features, the RBD-neurodegenerative disease association, evolving concepts, controversies, and future directions.
        Ann N Y Acad Sci. 2010; 1184: 15-54
        • Genier Marchand D.
        • Montplaisir J.
        • Postuma R.
        • et al.
        Detecting the cognitive prodrome of dementia with Lewy bodies: a prospective study of REM sleep behavior disorder.
        . 2017; 40https://doi.org/10.1093/dleep/zsw014
        • Mak E.
        • Su L.
        • Williams G.
        Longitudinal assessment of global and regional atrophy rates in Alzheimer’s disease and dementia with Lewy bodies.
        Neuroimage Clin. 2015; 7: 456-462
        • Watson R.
        • O’Brien J.
        Differentiating dementia with Lewy bodies and Alzheimer’s disease using MRI.
        Neurodegener Dis Manag. 2012; 2: 411-420
        • Klein J.
        • Eggers C.
        • Kalbe E.
        • et al.
        Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.
        Neurology. 2010; 74: 885-892
        • Graff-Radford J.
        • Murray M.
        • Lowe V.
        • et al.
        Dementia with Lewy bodies: basis of cingulate island sign.
        Neurology. 2014; 83: 801-809
        • Piggot M.
        • Marshall E.
        • Thomas N.
        • et al.
        Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution.
        Brain. 1999; 122: 1449-1468
        • Lobotesis K.
        • Fenwick J.
        • Phipps A.
        • et al.
        Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.
        Neurology. 2001; 56: 643-649
        • Rossi C.
        • Volterrani D.
        • Nicoletti V.
        • et al.
        ‘Parkinson-dementia’ diseases: a comparison by double tracer SPECT studies.
        Parkinsonism Relat Disord. 2009; 15: 762-766
        • Hall S.
        • Ohrfelt A.
        • Constantinescu R.
        • et al.
        Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
        Arch Neurol. 2012; 69: 1445-1452
        • Vanderstichele H.
        • De Vreese K.
        • Blennow K.
        • et al.
        Analytical performance and clinical utility of the INNOTESTVR PHOSPHO-TAU (181P) assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies.
        Clin Chem Lab Med. 2006; 44: 1472-1480
        • Abdelnour C.
        • van Steenoven I.
        • Londos E.
        • et al.
        Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia.
        Mov Disord. 2016; 31: 1203-1208
        • Kraybill M.
        • Larson E.
        • Tsuang D.
        • et al.
        Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.
        Neurology. 2005; 64: 2069-2073
        • Stinton C.
        • McKeith I.
        • Taylor J.
        • et al.
        Pharmacological management of Lewy body dementia: a systematic review and meta-analysis.
        Am J Psychiatry. 2015; 172: 731-742
        • Takahashi H.
        • Yoshida K.
        • Sugita T.
        • et al.
        Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series.
        Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 549-553
        • Cummings J.
        • Street J.
        • Masterman D.
        • et al.
        Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies.
        Dement Geriatr Cogn Disord. 2002; 13: 67-73
        • Walker Z.
        • Grace J.
        • Overshot R.
        • et al.
        Olanzapine in dementia with Lewy bodies: a clinical study.
        Int J Geriatr Psychiatry. 1999; 14: 459-466
        • Workman R.
        • Orengo C.
        • Bakey A.
        • et al.
        The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease.
        J Neuropsychiatry Clin Neurosci. 1997; 9: 594-597
        • Matsunaga S.
        • Kishi T.
        • Yasue I.
        • et al.
        Cholinesterase inhibitors for Lewy body disorders: a meta-analysis.
        Int J Neuropsychopharmacol. 2015; 19 ([pii:pyv086])
        • Wesnes K.
        • Aarsland D.
        • Ballard C.
        • et al.
        Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies.
        Int J Geriatr Psychiatry. 2015; 30: 46-54
        • Matsunaga S.
        • Kishi T.
        • Iwata N.
        Memantine for Lewy body disorders: systematic review and meta-analysis.
        Am J Geriatr Psychiatry. 2015; 23: 373-383
        • Molloy S.
        • McKeith I.
        • O’Brien J.
        • et al.
        The role of levodopa in the management of dementia with Lewy bodies.
        J Neurol Neurosurg Psychiatry. 2005; 76: 1200-1203
        • Bonelli S.
        • Ransmayr G.
        • Steffelbauer M.
        • et al.
        L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.
        Neurology. 2004; 63: 376-378
        • Goldman J.
        • Goetz C.
        • Brandabur M.
        • et al.
        Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies.
        Mov Disord. 2008; 23: 2248-2250
        • Baker W.
        • Silver D.
        • White C.
        • et al.
        Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis.
        Parkinsonism Relat Disord. 2009; 15: 287-294
        • Chiu P.
        • Wang C.
        • Tsai C.
        • et al.
        Depression in dementia with Lewy bodies; a comparison with Alzheimer’s disease.
        PLoS One. 2017; 12: e0179399
        • Culo S.
        • Mulsant B.
        • Rosen J.
        • et al.
        Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial.
        Alzheimer Dis Assoc Disord. 2010; 24: 360-364
        • Kramberger M.
        • Auestad B.
        • Garcia-Ptacek S.
        • et al.
        Long-term cognitive decline in dementia with Lewy bodies in a large multicenter, international cohort.
        J Alzheimers Dis. 2017; 57: 787-795
        • Blanc F.
        • Mahmoudi R.
        • Jonveaux T.
        • et al.
        Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse.
        Alzheimers Res Ther. 2017; 9: 47
        • Ricci M.
        • Guidoni S.
        • Sepe-Monti M.
        • et al.
        Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD).
        Arch Gerontol Geriatr. 2009; 49: e101-e104
        • Bostrom F.
        • Jonsson L.
        • Minthon L.
        • et al.
        Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease.
        Alzheimer Dis Assoc Disord. 2007; 21: 150-154
        • Rongve A.
        • Vossius C.
        • Norse S.
        • et al.
        Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia.
        Int J Geriatr Psychiatry. 2014; 29: 392-398
        • Murman D.
        • Juo S.
        • Powel M.
        • et al.
        The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies.
        Neurology. 2003; 61: 944-949
        • Vardy E.
        • Holt R.
        • Gerhard A.
        History of a suspected delirium is more common in dementia with Lewy bodies than Alzheimer’s disease: a retrospective study.
        Int J Geriatr Psychiatry. 2014; 29: 178-181